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Abstract
Objectives In this review, we focus on the application of clustered regularly interspaced short palindromic repeats (CRISPR)/
CRISPR associated nuclease 9 (Cas9), as a powerful genome editing system, in the identification of resistancemechanisms and in
overcoming drug resistance in the most frequent solid tumors.
Data acquisition Data were collected by conducting systematic searching of scientific English literature using specific keywords
such as Bcancer^, BCRISPR^ and related combinations.
Results The review findings revealed the importance of CRISPR/Cas9 system in understanding drug resistance mechanisms and
identification of resistance-related genes such asPBRM1, SLFN11 and ATPE1 in different cancers.We also provided an overview
of genes, including RSF1, CDK5, and SGOL1, whose disruption can synergize with the currently available drugs such as
paclitaxel and sorafenib.
Conclusion The data suggest CRISPR/Cas9 system as a useful tool in elucidating the molecular basis of drug resistance and
improving clinical outcomes.
Keywords Solid tumor . CRISPR/Cas9 . Targeted therapy . Drug resistance . Drug response . Clinical outcome
Background
Cancer is a multi-factorial disease and genetics play an impor-
tant role in the tumorigenesis process. The formation of cancer
cells is a long-term process and it can take several years for a
normal cell to turn into a cancer cell. Several genetic changes
are accumulated in normal cells over time and this eventually
results in cancer [1]. Sometimes, cancer cells can be
Baddicted^ to a certain molecule. This means targeting a spe-
cific gene/molecule in tumor cells can lead to cell death. For
instance, genomic aberrations in genes such as EGFR, HER2,
MET and ALK can make a normal cell cancerous [2].
Therefore, targeting these molecules or related pathways by
chemical inhibitors such as tyrosine kinase inhibitors (TKIs),
i.e. gefitinib, afatinib or crizotinib, can lead to significant in-
hibition of tumor growth. However, eventually, tumor cells
become resistant to the treatment due to the emergence of a
new bypass mechanisms which could be via acquiring new
genomic aberrations [3, 4]. For instance, acquiring EGFRmu-
tation (T790 M), amplification of MET proto-oncogene (a
receptor tyrosine kinase) and AXL activation are proven cause
of resistance against EGFR-TKIs in lung cancer patients [5].
Overall, a wide range of cellular mechanisms including
epithelial-mesenchymal transition (EMT), changes in autoph-
agy and glycolysis, suppression of apoptosis, epigenetic mod-
ifications and alteration in the drug metabolism can lead to
drug resistance in different types of cancer [3, 6]. These new
genomic changes can be either induced by treatment or orig-
inated from intratumor heterogeneity [3, 7]. Thus, treatment
strategy should be modified based on the new molecular sig-
nature of the tumor.
CRISPR/Cas9 gene editing technology has dramatically
influenced the field of molecular biology. It is a very flexible,
powerful and convenient gene manipulation tool which is
used for a wide range of purposes including elucidation of
protein function [8, 9], investigation of molecular basis of
cancer by generating in vivo and in vitro models [10, 11] and
Ali Saber and Bin Liu contributed equally to this work.
* Hidde J. Haisma
h.j.haisma@rug.nl
1 Department of Chemical and Pharmaceutical Biology, Groningen
Research Institute of Pharmacy, University of Groningen,
Groningen, The Netherlands
2 Universal Scientific Education and Research Network, Tehran, Iran
3 Parseh Medical Genetics Clinic, Tehran, Iran
DARU Journal of Pharmaceutical Sciences
https://doi.org/10.1007/s40199-019-00240-z
identification of drug resistance mechanisms [12, 13].
Besides, one of the most valuable applications of CRISPR/
Cas9 system is to investigate the role of different genes in the
improvement of drug response. It can be employed to modify
genomic DNA at single nucleotide level or to knockout a
certain gene in cancer cells to functionally study the effect of
these modifications in treatment response. Therefore,
CRISPR/Cas9 can provide the opportunity to study drug re-
sistance in different cancer types resulting in the identification
of several resistance-related genes. These genes can be either
genetically disrupted or pharmaceutically inhibited, if they are
overexpressed in tumor cells resulting in resensitization of the
cells to treatment.
Recently, few review articles have been published mainly
focusing either on the application of CRISPR/Cas9 technolo-
gy in cancer treatment and on drug resistance in breast cancer
[14, 15]. In this review, we specifically focus on drug resis-
tance and identification of different target genes to overcome
drug resistance in different cancer types which can improve
clinical outcomes. Thus, we present an overview of CRISPR-
based pre-clinical studies associated with drug resistance in a
number of solid tumors including lung, breast, liver and brain
cancer.
Data acquisition
Data were collected from PubMed by using specific keywords
such as BCRISPR^ in combination with other related-
keywords including lung, breast, liver, glioma, ovarian, colon
and testicular cancer, tumor or malignancy. Our search result-
ed in 369 English articles containing both CRISPR and one of
the cancers in either title or abstract. Only articles with a focus
on drug resistance were included in this review. After skim-




CRISPR/Cas9 is part of prokaryotic immune system, which is
used as a defense mechanism to disrupt foreign plasmids and
viruses. It consists of two main subunits: a single-guide RNA
(sgRNA) and Cas9 nuclease. Cas9 is usually derived from
Streptococcus pyogenes and contains two nuclease domains
(HNH and RuvC-like nuclease domains) which can cut dou-
ble stranded DNA. The HNH domain cleaves the complemen-
tary DNA strand while the RuvC-like domain cuts the non-
complementary strand. Single-guide RNA is responsible for
the recognition of the target site via a 20-nucleotide sequence
which is complementary to the target sequence [16–18]. It
directs Cas9 to the target site and then, Cas9 cleaves the ge-
nomic DNA resulting in a double stranded break (DSB).
Subsequently, the genomic DNA is repaired either by non-
homologous end joining (NHEJ) or homology directed
DNA repair (HDR) (Fig. 1). NHEJ usually results in small
insertion/deletions (indels) and gene knockout, whereas
HDR works more precisely and results in point mutations or
gene knockin [19]. Basically, any gene of interest can be
targeted by small modifications in the sgRNA sequence.
However, the selected target sequence must be immediately
downstream of a protospacer adjacent motif (PAM), a short
sequence (5’-NGG-3′), that is recognizable by Cas9 nuclease
[16, 20].
CRISPR/Cas9 system and drug response in solid
tumors
Many genomic aberrations, such as chromosomal rearrange-
ments, activating mutations in oncogenes, loss of function
mutations in tumor suppressor genes and epigenetic events
are needed to convert a normal cell to a cancer cell [21, 22].
Tumor cells may respond to treatment depending on their
molecular signature. However, resistance inevitably arises
and new treatment strategies are required. The CRISPR/
Cas9 genome editing system can precisely introduce activat-
ing or loss of function mutations into the tumor genome en-
abling researchers to explore the role of different genes in
tumorigenesis.
In addition, the CRISPR/Cas9 editing system can be uti-
lized to get insight into the molecular mechanisms underlying
drug resistance as well as targeting specific oncogenes either
as monotherapy or in combination with currently available
drugs (Table 1) [12, 13, 24, 42, 60]. CRISPR/Cas9 system
can be used to correct resistant form of a certain targetable
cancer-related gene and resensitize tumor cells to the treat-
ment. Moreover, CRISPR/Cas9 can be engineered to disrupt
resistance-related oncogenes such as KRAS or to correct cer-
tain tumor suppressor genes such as TP53 resulting in
resensitization of tumor cells.
Although CRISPR/Cas9 is a powerful tool for gene manip-
ulation at the single base pair resolution, the vast majority of
studies are focused on the knockout of certain genes in differ-
ent cancers. Below, we only focus on CRISPR-based studies
associated with drug response and resistance in the most fre-
quent solid tumors including lung, breast, liver and brain
cancers.
Lung cancer
Lung cancer is the main cause of cancer-related death in the
word with a very poor prognosis [5]. As abovementioned,
primary or secondary drug resistance in lung cancer patients
is the main reason for researchers to look for new treatment
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strategies. Therefore, CRISPR/Cas9 technology would be of
great benefit to directly target certain genes or to improve the
drug response.
EGFR ex20isn is responsible for less than 10% of the
EGFR mutations in non-small cell lung cancer (NSCLC) pa-
tients. However, unlike EGFR ex19del and L858R activating
mutations, conventional chemotherapy is still the standard
treatment for this subset of patients. A recent study investigat-
ed the potential therapeutic activity of osimertinib, a TKI used
against resistant tumor cells harboring T790 M mutation, on
NSCLC cells containing ex20ins. They established an EGFR
ex20ins adenocarcinoma cell line using CRISPR/Cas9 and
showed that osimertinib can inhibit the proliferation in tumor
cells harboring this specific mutation in vitro as well as inhi-
bition of the ex20ins-mediated pathway in vivo [23].
Recently, it has been shown that proteins involved in tran-
scriptional complexes play a role in drug response. Terai et al.
(2018) exploited a genome-wide CRISPR approach in com-
bination with erlotinib (an EGFR-TKI) and THZ1 (CDK7/12
inhibitor) to overcome drug resistance in an EGFR-dependent
lung cancer cell line (PC9). Interestingly, deletion of multiple
genes involved in transcriptional complex including MED1,
CREBBP and EP300 increased erlotinib/THZ1 synergy [24].
Thus, multiple sgRNAs that can target one or more of the
abovementioned genes in combination with EGFR-TKIs such
as erlotinib might be a better treatment option for EGFR-
dependent tumors as compared to monotherapy. A combina-
tion of sgRNAs and shRNAs was used in lung cancer cells
(PC9) treated with gefitinib resulted in the identification of
several subunits of the SWI/SNF complex (a nucleosome re-
modeling complex) including PBRM1, ARID2, and ARID1A
as a role player in cell survival and drug resistance.
Furthermore, loss of PBRM1 attenuated the effect of gefitinib
and prolonged survival of the cells treated with erlotinib [27].
In another study, deletion of insulin-like growth factor 1 re-
ceptor (IGF1R) in HCC827 lung cancer cells selectively in-
duced erlotinib resistance viaMET amplification as compared
to the wildtype resistant cells [28].
KEAP1 is mutated in 20% of lung adenocarcinoma tumors
and is involved in the oxidative stress response. KEAP1 tar-
gets NFE2L2/NRF2 for ubiquitination and proteasomal deg-
radation. A genome wide CRISPR/Cas9 drug resistance
screening study revealed that loss of KEAP1 confers multiple
drug resistance to different lung cancer cells, i.e. H1299,
CALU1 and HCC364, through elevated NRF2 activity [12].
In addition, CRISPR-mediated loss of function of Keap1 pro-
moted lung cancer in a Kras-driven mouse models and caused
glutaminolysis dependent lung tumors which can be inhibited
by anti-glutaminase drugs [61]. As loss of KEAP1 is involved
in drug resistance, restoring its expression in KEAP1 mutated
tumors may resensitize tumor cells to the treatment. However,
further in vivo studies are needed to investigate the effect of
NRF2 depletion on KEAP1 mutated tumors.
Wright et al. (2017) showed that polo-like kinase 1 (PLK1)
can be targeted by AZD1775, a WEE1 tyrosine kinase inhib-
itor. They showed that CRISPR-mediated knockout ofWEE1
sensitized lung cancer cells (H322) to AZD1775 to a similar
level as BI-2536, a potent PLK1 inhibitor [62]. Aurora-B is a
protein kinase which is involved in the regulation of cell divi-
sion. A recent study investigated the role of this protein in
NSCLC resistance to chemotherapy. It was shown that abla-
tion of Aurora-B resensitized NSCLC cancer cells to cisplatin
[25]. Remodeling and spacing factor 1 (RSF1) is a protein
involved in chromatin remodeling and transcriptional regula-
tion. Disruption ofRSF1 in A549 and H1299 lung cancer cells
promoted apoptosis, reduced cell proliferation and increased
Fig. 1 The mechanisms of
CRISPR/Cas9-mediated genome
editing and double-strand breaks
(DSBs) repair. CRISPR/Cas9 can
introduce DSBs in DNA. The
DSBs is repaired by either non-
homologous end joining (NHEJ)
or homology-directed repair
(HDR). Insertions, deletions or
other alterations of DNAwill
occur during this process to
achieve gene modifications.
PAM: protospacer adjacent motif;
sgRNA: single-guide RNA
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sensitivity to paclitaxel, a chemotherapeutic compound [26].
Taken together, it seems that the origin of the tumor cells, their
genetic makeup and whether the tumor cells rely on a specific
molecule for proliferation play important roles in the selection
of right targets for lung cancer treatment.
CRISPR/Cas9 has been exploited in several studies to in-
vestigate potential resistance mechanisms to conventional
therapies including chemotherapy and radiotherapy.
Inducing specific mutations inMUC16, a member of the mu-
cin family glycoproteins, resulted in resistance to chemother-
apy (cisplatin) and conferred more aggressive characteristics
to the cells [29]. In another study, disruption of CDKN1A
(P21) resulted in resistance of lung cancer cells to radiation
therapy suggesting its crucial role in lung cancer treatment
response [30]. Expression analysis of more than 12,000 genes
revealed SLFN11 as a significant potential determinant of
poly-(ADP)-ribose polymerase (PARP) inhibitor activity in
small cell lung cancer. In addition, CRISPR-mediated deletion
of SLFN11 caused resistance to talazoparib, a PARP inhibitor,
in vitro. Moreover, the response to talazoparib was strongly
depended on the expression level of SLFN11 [31]. Overall,
these findings indicate how resistance mechanisms can be
defined by different molecules in tumor cells. Therefore, de-
pending on the effect of the protein on the treatment outcomes,
restoration or deletion of that specific protein could be bene-
ficial for the patients. In addition, sgRNAs targeting certain
genes could concomitantly be used with the currently avail-
able drugs to improve clinical outcomes. However, as lung
tumors are very heterogeneous [7, 63], outgrowth of a minor
resistant clone might occur.
Breast cancer
Breast cancer is the most common type of cancer and the main
cause of cancer-related death in women worldwide [64]. It is
classified into four main molecular subtypes based on the
expression of different markers, i.e. progesterone receptor
(PR), estrogen receptor (ER), ERBB2 (HER2), p53 and Ki-
67 [65]. Drug resistance occurs in almost 30% of the cases
with ER-positive luminal subtypes which are the most com-
mon type of breast cancer. Thus, identification of new strate-
gies that can fundamentally influence drug resistance is criti-
cal. This can be done either by direct depletion of driver genes
or resensitizing tumor cells to the treatment by suppression of
drug resistance-related genes that can synergize with specific
drugs.
Pharmacogenetics studies have shown that germline genet-
ic variants can have a great impact on the metabolism of spe-
cific drugs. In other word, the response to treatment can be
influenced by the inherited genetic variants. A single nucleo-
tide polymorphisms (SNP) (rs9940645) in ZNF423 gene pre-
dicts the response to the selective estrogen receptor modula-
tors (SERMs) in breast cancer patients. ZR75–1 cells, which
are positive for ERα and contain the rs9940645 variant, were
CRISPR-engineered to generate wildtype cells by Qin et al.
(2017). The authors showed that the cells containing the var-
iant are more sensitive to raloxifene, olaparib and cisplatin
[32]. Beside the germline variants, somatic mutations in the
frequently mutated genes such as ESR1 (ERα) in breast tumor
cells can also affect the response to treatment. For instance,
genetically modified T47D andMCF7 breast cancer cells con-
taining mutations in ESR1 (Y537S and D538G mutations)
showed estrogen-independent growth and resistance to
fulvestrant, raloxifene and 4-Hydroxytamoxifen (4-OHT)
in vitro [36–38]. Further in vivo studies are needed to investi-
gate the role of different genetic variants on the response of
tumor cells to specific drugs. Hence, inducing specific nucle-
otide changes in the breast cancer tumor cells may improve
treatment outcomes in the near future.
CRISPR/Cas9 genome editing tools have been used in dif-
ferent studies to identify whether clinically available drugs for
other cancer types can also be effective in breast cancer.
Weyburne and colleagues genetically ablated proteasome β2
resulting in the sensitization of triple-negative breast cancer
(TNBC) cells to the proteasome inhibitors bortezomib and
carfilzomib, drugs commonly used for the treatment of multi-
ple myeloma, in vitro and in vivo [33]. Another study revealed
strong synergy of E-cadherin inhibition with clinically avail-
able ROS1 inhibitors, foretinib and crizotinib, in breast cancer
cells both and in vivo [34]. These sorts of studies can save
considerable amount of time for the development of new
drugs in different types of cancer.
Non-coding RNAs play important roles in the cells and
their dysregulation in various types of cancer including breast
tumors have been reported previously. Knockout of long non-
coding RNA RoR (linc-RoR) in MCF7 breast cancer cells
promoted the MAPK/ERK signaling pathway indicating its
oncogenic role in breast cancer. Furthermore, depletion of
linc-RoR sensitized breast cancer cells to tamoxifen, a drug
commonly used for the treatment of breast cancer [35]. These
data suggest that suppression of non-coding RNAs could be
an effective approach to improve clinical outcomes.
CRISPR/Cas9 technology, either as a single gene manipu-
lation tool or as a genome wide screening method, has been
extensively used to understand resistance mechanisms in
breast cancer. This has led to the identification of several mol-
ecules with a role in drug resistance. Genetic ablation of
ATPE1, a base excision repair enzyme, in TNBC cells
(HCC1937) led to resistance to olaparib [39]. Disruption of
WAVE3, a member of the WASP/WAVE actin-cytoskeleton
remodeling family, substantially attenuated cancer stem cell
(CSC) populations in TNBC cell lines through suppressing
CSC self-renewal capacity and transcriptional regulation of
CSC-specific genes. These results support the critical role of
WAVE protein in TNBC chemoresistance [66]. CRISPR-
based knockout ofMAP3K1 in mutant PIK3CA breast cancer
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cell lines resulted in an increased proliferation rate and de-
creased sensitivity to an AKT inhibitor (AZD5363) through
enhanced phosphorylation of AKT in vitro as well as in vivo
[40]. In addition, disruption of FUT8 significantly reduced
cell invasion and metastatic abilities in vivo by suppressing
EMTwhich is a well-known drug resistance mechanism [67].
A genome-wide CRISPR screening revealed that single
deletion of BAK or double deletion of BAK/BOX confers re-
sistance of the cells against S63845, a MCL-1 inhibitor [41].
Thu and colleagues (2018) used the samemethod and revealed
that genetic ablation of any components of the anaphase-
promoting complex/cyclosome (APC/C), i.e. MAD2L1BP,
ANAPC4 and ANAPC13 can confer resistance to CFI-
402257, a TTK protein kinase inhibitor [13]. Another genome
wide CRISPR/Cas9 screening study revealed that ablation of
any CST complex member, i.e. Ctc1, Stn1 or Ten1, confers
resistance to PARP inhibitors inBRCA1 deficient breast cancer
cells in vivo [42]. In summary, CRISPR/Cas9 helped to iden-
tify several novel resistance mechanisms to a wide range of
drugs including PARP inhibitors. It can also significantly im-
prove the drug response to SERMs in breast cancer. These
findings may push pharmaceutical companies to generate
new compounds which can overcome drug resistance.
Liver cancer
Liver cancer is the second cause of cancer-related death in the
world. It has limited treatment options and the majority of the
patients experience tumor recurrence [68]. Therefore, a better
understanding of drug resistance mechanisms and identifica-
tion of new treatment options in this cancer seems vital.
Sorafenib is a multikinase inhibitor which is commonly
used for treatment of liver cancer patients. Recently, several
research groups have utilized CRISPR-based methods to un-
derstand the potential resistance mechanisms and increase the
efficacy of sorafenib in hepatocellular carcinoma (HCC).
Suppression of cyclin dependent kinase 5 (CDK5) combined
with sorafenib resulted in a reduced cell proliferation and mi-
gration as well as suppression of HCC progression both
in vitro and in vivo by interfering with intracellular trafficking
mechanisms [43]. It has been shown that knockout of the
fibroblast growth factor receptor (FGFR4) using CRISPR
technology sensitizes HCC cancer cells to sorafenib [44]. A
CRISPR-based screening study, with focus on kinases, re-
vealed that disruption of MAPK1 (ERK2) has a synergistic
effect with sorafenib alone or a combination of sorafenib and
selumetinib in HCC cell line (HuH7) by suppression of cell
proliferation [45].
A genome wide CRISPR screening study revealed that loss
of SGOL1, a protein involved in mitosis, is the main cause of
resistance to sorafenib in HuH7 and SMMC-7721 HCC cells.
Further in vivo studies showed decreased sorafenib cytotoxic-
ity and increased tumor size supporting contribution of
SGOL1 to sorafenib resistance [46]. These findings suggest
that SGOL1 might be a suitable therapeutic target for HCC
patients and individuals with SGOL1 overexpression might be
appropriate candidates to be treated with sorafenib. In addi-
tion, serial sampling during treatment and assessment of
SGOL1 expression levels might be used as a putative resis-
tance biomarker in HCC patients which demands further in-
vestigation. Together, these data show that clinical outcomes
in liver cancer patients may be improved by suppression of
specific proteins such as CDK5, FGFR4 and MAPK1, espe-
cially when it is combined with drugs like sorafenib.
Gliomas
Malignant glioma is the most common type of brain primary
tumor and is divided into different subtypes. Glioblastoma
multiforme (GBM) is responsible for approximately 70% of
all gliomas and it is the most aggressive form of brain cancer
with a poor prognosis. GBM is highly heterogeneous which
may promote the chance of drug resistance [69, 70]. Thus,
CRISPR/Cas9 would be a valuable method to identify genes
involved in glioma pathogenesis and drug resistance.
Several studies have investigated the role of different pro-
teins such as ATRX, NOTCH1, PCM1 and GLI1 in the re-
sponse to various types of treatment such as chemo- and radi-
ation therapy in gliomas using CRISPR/Cas9 system.
Deletion of ATRX increased the sensitivity of the tumor cells
both in vitro and in vivo to temozolomide, a commonly used
chemotherapeutic agent [47]. Overexpression of NOTCH1,
which is a transmembrane protein, is associated with poorer
overall survival in GBM patients. NOTCH1 CRISPR-
mediated knockout in U87 and U251 glioblastoma cells
showed a significant synergistic effect with radiation therapy
[48]. Depletion of PCM1, a component of centriolar satellites,
resulted in the inhibition of glioblastoma cell proliferation. In
addition, PCM1 ablation promoted apoptosis and increased
the sensitivity to temozolomide in patient-derived GBM cell
lines [49]. Knockout of GLI1, also known as glioma-
associated oncogene, in combination with penfluridol (an an-
tipsychotic drug) showed increased apoptosis in primary glio-
blastoma cells [50]. These findings indicate that combination
of genetic modifications as a supplementary treatment with
conventional therapies may increase the efficacy of the treat-
ment in glioma patients.
Discussion and conclusion
Based on the data presented here, several drug response-
related genes have been identified using CRISPR/Cas9 ge-
nome editing system. Reactivation or suppression of these
genes/proteins may resensitize tumor cells to treatment and
improve the drug response.
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It has been shown that deletion of genes such as KEAP1
and CDKN1A results in drug resistance [12, 30]. Thus, maybe
restoration of these proteins specifically in the tumor cells can
resensitize them to the treatment. This can also be applied
conversely. For instance, CRISPR-mediated deletion of a spe-
cific gene such as MAPK1 and CDK5 in cancer cells leads to
suppression of the tumor cell growth and sensitization of the
cells to treatment [43, 45]. Inducing loss of function mutations
in these genes in the tumor cells may inhibit tumor growth and
have a synergistic effect with a specific drug. However, how
we can deliver the Cas9/sgRNAs only to the tumor cells with-
out hurting normal cells still remains challenging. Therefore,
one of the core topics of delivery is minimizing off-target
effects by strategies that can specifically target tumor cells,
such as using specific promoters and highly expressed surface
receptors on cancer cells.
In addition, certain genetic variants can influence treatment
outcomes. Thus, another strategy which might be useful is to
induce specific nucleotide changes in certain genes in cancer
cells to make themmore vulnerable to treatment. For example,
inducing specific genetic changes in ESR1 and ZNF423 in
breast cancer cells followed by fulvestrant, raloxifene or
olaparib treatment can significantly affect the tumor response
[32, 36–38] which may be an option to improve the clinical
outcomes in patients. Moreover, emerging new mutations in
EGFR (p.T790 M) and ALK-EML4 (p.G1269A) can lead to
acquired drug resistance in NSCLC patients [71–73].
Replacing these drug resistance causing mutations with the
responsive variants can resensitize tumor cells to the same
treatment.
Tumor heterogeneity is another challenge in using
CRISPR/Cas9 technology as a therapeutic tool in cancer pa-
tients. Tumors usually contain one or more dominant clones
and several minor subclones [7, 74, 75]. When patients are
treated with a specific drug, tumor cell populations go through
selection pressure. Thus, the dominant clones which are sen-
sitive to the treatment are killed leading to the outgrowth of
one or more resistant subclones. This can also happen if the
tumor cells are treated with specific Cas9/sgRNAs targeting a
certain gene and eventually resistance arises. However, treat-
ment of the tumor cells with multiple Cas9/sgRNAs, targeting
a number of resistance-related genes, might be an option to
tackle this problem.
Despite all opportunities provided by CRISPR/Cas9 sys-
tem in cancer therapy, there are still some social and ethical
concerns that have to be addressed. Safety is the primary issue
for the application of CRISPR-based technologies due to pos-
sible off-target effects as well as continuous activity of Cas9.
In addition, lack of an efficient in vivo delivery method with
high specificity is another issue that has to be solved.
Therefore, safety of CRISPR/Cas9 system must be confirmed
and validated before it is clinically available. Justice and eq-
uity is another concern; whether CRISPR-based treatments
are available and affordable for everyone. Meanwhile, ge-
nome editing research involving embryos and clinical
germline genome editing are other ethical issues related to
CRISPR/Cas9 technologies that need to be taken into account.
In conclusion, although delivery of the CRISPR/Cas9 and
off-target effects remains a challenge, CRISPR-based
methods are promising and useful tools for cancer treatment,
identification of resistance mechanisms and overcoming drug
resistance.
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